Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06613243
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
Different Doses of Dexmedetomidine Combined With Esketamine in Women Undergoing Cesarean Delivery
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Different Doses of Dexmedetomidine Combined With Esketamine for Analgesia in Women Undergoing Cesarean Delivery a Pilot Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Esketamine is a commonly used analgesic during cesarean delivery but may produce transient neuropsychiatric symptoms Dexmedetomidine has both sedative and analgesic effects When used in combination with esketamine dexmedetomidine can reduce esketamine related neuropsychiatric effects after general anesthesia The investigator speculate that combining low-dose dexmedetomidine with esketamine may also reduce neuropsychiatric adverse effects of esketamine in women undergoing cesarean section This pilot trial is designed to determine the minimum dose of dexmedetomidine that can effectively prevent neuropsychiatric side effects of antidepressive dose esketamine 02mgkg in women undergoing cesarean delivery
Detailed Description:
Esketamine is a commonly used anesthetic and analgesic drug during the perioperative period Recent studies found that low-dose esketamine has rapid onset antidepressant effects and reduces postpartum depression when administered during cesarean delivery However even low-dose esketamine produces transient neuropsychiatric symptoms
Dexmedetomidine is a high selective alpha2-adrenoceptor agonist and has both sedative and analgesic effects When used in combination with esketamine dexmedetomidine reduces esketamine related neuropsychiatric adverse reactions in patients undergoing general anesthesia
The investigator speculate that combining low-dose dexmedetomidine with esketamine may also reduce neuropsychiatric adverse effects of esketamine in women undergoing cesarean delivery The purpose of this pilot trial is to determine the minimum dose of dexmedetomidine that can effectively prevent neuropsychiatric side effects of antidepressve dose esketamine 02mgkg in women undergoing cesarean delivery
Dexmedetomidine is a high selective alpha2-adrenoceptor agonist and has both sedative and analgesic effects When used in combination with esketamine dexmedetomidine reduces esketamine related neuropsychiatric adverse reactions in patients undergoing general anesthesia
The investigator speculate that combining low-dose dexmedetomidine with esketamine may also reduce neuropsychiatric adverse effects of esketamine in women undergoing cesarean delivery The purpose of this pilot trial is to determine the minimum dose of dexmedetomidine that can effectively prevent neuropsychiatric side effects of antidepressve dose esketamine 02mgkg in women undergoing cesarean delivery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None